CIPLA Ltd - Positive Outlook Despite Regulatory Challenges
Cipla reported the highest-ever US business to the tune of $204 Mn (+5% QoQ), which was majority led by better execution in the base business and a...
345 Views
Cipla Ltd. - Momentum Continues Led by Market Share Gain
The US business reported strong sales of $195 Mn (vs. exp. $190 Mn) which is contributed by gRevlimid, gLeuprolide, and gLanreotide.
438 Views
Axis Research Scorecard Report - Mar 2022
Axis Top Picks basket has delivered an astounding return of 127% since its inception, notably beating the 89% return reported by the benchmark...
331 Views
Cipla: Rigor on Portfolio Execution and Cash Generation Initiatives to Support Growth
We initiate coverage on CIPLA Ltd (CIPLA) with a BUY rating and a target price of Rs 1,200 (PE 24x for FY24E EPS), implying an upside of 15.5% from...
371 Views
Superior execution drives India/US performance
CIPLA delivered a better-than-expected 3QFY22 performance, led by robust growth in the Domestic Formulation (DF) segment, steadily improving sales...
318 Views